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Abstract. The trial and error of the pioneering xenotransplant trials over 
the past three decades has defined the limitation of the species used. 
Success was tantalizingly close with the chimpanzee, baboon, and other 
primates. The use of more disparate species has been frustrated by the 
xenoantibody barrier. Future attempts at clinical xenotransplantation 
will be hampered by the consideration of the species of animals and the 
nature of the organs to be transplanted. On one hand, primate donors 
have the advantage of genetic similarity (and therefore potential compat-
ibility) and less risk of Immunologic loss. On the other hand, pig donors 
are more easily raised, are not sentient animals, and may be lli:ss likely to 
harbor transmissible disease. It is recognized that the success of xeno-
transplantation may very with dlft'erent organs. Because it is relatively 
resistant to antibody-mediated rejection, the liver is the organ for which 
there is the greatest chance of long-term success. Consideration of using 
xenotransplants on a temporary basis, or as a "bridge" to permanent 
human transplantation. may allow clinical trials utilizing hearts or 
kidney xenografts. Issues on metabolic compatibility and infection risks 
cannot be accurately determined until routine success in clinical xeno· 
transplantation occurs. Based on a limited experience, the conventional 
approaches to allotransplantation are unlikely to be successful in xeno-
transplantation. The avoidance of immediate xenograft destruction by 
hyperacute rejection, achieved using transgenic animals bearing human 
complement regulatory proteins or modulating the antigenic target on the 
donor organ, is the first step to successful xenotransplantation. The 
ability to achieve tolerance by establishing a state of bone marrow 
chimerism is the key to overcoming the long-term immunologic insults 
and avoiding the necessarily high doses of nonspecific immunosuppres-
sion that would otherwise be required and associated with a high risk of 
infectious complications. Xenotransplantation faces criticish"1 that is 
strongly reminiscent of that leveled against human-to-human transplan-
tation during the late 19605 and early 19705. Yet with persistence, the field 
of human·to·human transplantation has proved highly successful. This 
success was the result of a stepwise increase in our understanding of the 
biology of rejection, Improvements in drug management, and experience. 
It is possible that xenotransplantation may not be universally successful 
until further technologic advances occur; yet cautious exploration of 
xenotransplantation appears warranted to identify those areas that 
!"eq!.~!~ !!!~!!e!" :~!!!,fS 
Organ transplantation has become an effective means for treating 
patients with end-stage organ failure. This achievement can be 
largely attributed to the development of advanced technical skills 
and the availability of new immunosuppressive agents. such as 
cyclosporine and tacrolimus. Patients undergoing organ trans-
plantation experience excellent likelihood of survival with good 
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quality of life. This success has increased the demand for organ 
transplantation, and thus an estimated 75,000 Americans suffering 
from end-stage organ failure currently await or receive a life-
saving organ transplantation each year. However, almost 10% of 
patients awaiting transplantation die because of the lack of 
availability of human organs each year [1]. Despite heightened 
public awareness to address the need for organ donation, there 
appears to be little prospect of increasing donation to meet the 
current needs. 
It is widely anticipated that the only means of addressing this 
shortage is by the development of artificial organs or utilizing 
organs from species other than humans (or both) and has inspired 
concerted research efforts in the field of xenotransplantation. 
Although artificial organs may become reality with future devel-
opments, their ability to replace complex organs, such as the liver, 
is probably years away. Without the benefit of artificial support of 
patients with liver, heart, or lung failure, transplantation of 
functioning organs is the only alternative to death. Thus xeno-
transplantation represents the most promising alternative to the 
current organ shortage, especially with an increased understand-
ing of rejection mechanisms of both allografts (organs trans-
planted across the same species) and xenografts (organs trans-
planted across different species). 
Recent developments in understanding the barriers to success-
ful xenotransplantation have led to the application of novel drugs 
to manipulate the immune system. Along with the concept of 
microchimerism applied to xenotransplantation and bolstered by 
the utilization of genetically modified donor animals, application 
of new bioreagents to enhance microchimerism holds promise for 
future attempts at clinical xenotransplantation. 
Xenograft Immunity 
When organs are transplanted across closely related species (e.g., 
baboon to human), such xenotransplants are referred to as 
concordant. Organs implanted across widely divergent species 
(e.g., pig to human) are termed discordant. These two terms also 
characterize the extent of difficulty that exists in achieving suc-
cessful organ transplantation across these barriers [2]. It is much 
easier to achieve xenograft acceptance across concordant combi-
nations than with discordant combinations. A number of animal 
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models have been developed for both discordant and concordant 
xenotransplantation, but long-term successes have been limited, 
for the most part, to concordant combinations. The lack of 
high-titer preformed xenoantibodies in the concordant combina-
tions has avoided the almost immediate destruction of discordant 
xenografts, which has been difficult to prevent or treat. Neverthe-
less, even with the discordant combinations significant prolonga-
tion of xenograft survival has been reported utilizing antibody 
depletion [3] or removal of complement [4, 5]. These animal 
models of xenotransplantation have been used to learn more 
about the types of rejection and the drugs that can be utilized to 
reduce the threat of rejection. Combinations of drugs, each 
targeted at different limbs of the rejection pathway, have been 
shown to prolong xenograft survival significantly [6]. 
Across concordant barriers a major concern is cell-mediated 
immunity [8], a response similar to that encountered after allo-
transplantation and therefore somewhat controllable by the use of 
immunosuppressive drugs. In fact, in rodent models of xenotrans-
plantation, indefinite survival of concordant liver xenografts using 
standard doses of immunosuppressive agents has been reported 
[6]. In addition, historic attempts of primate-to-human transplants 
revealed that prolonged concordant xenograft function may be 
achievable [8]. What then is limiting the pursuit of concordant 
xenotransplantation? Several issues have been raised against 
utilizing primates as donors, including "humanization of pri-
mates," limited availability, donor size incongruity, and the theo-
retic risk of transmitting infectious agents [9, to]. These concerns 
have prompted a quest for alternative sources of animals for 
clinical xenotransplantation. It is widely anticipated that a species 
discordant with humans (e.g., pigs) may offer a source of organs 
for xenotransplantation. 
Pigs are available in sufficient quantities, have anatomy and 
physiology similar to that of humans, and can be bred under 
conditions where they can be genetically modified. These factors 
have prompted the consideration of this species as a source for 
clinical xenotransplantation, although organs from discordant 
species are confronted with a formidable barrier: hyperacute 
rejection mediated by naturally occurring antibodies (preformed 
xenoantibodies) present in the recipient [11]. Because of the 
difficulty of controlling this form of rejection, novel approaches 
are required to overcome this barrier to successful discordant 
xenotransplantation. In addition, other unknown factors, includ-
ing infection risks and metabolic compatibility, have not been 
addressed. 
One strategy to prevent hyperacute rejection is removal of 
preformed antibodies from the recipient's blood prior to trans-
plantation by plasmapheresis (nonspecific antibody removal) [12] 
or immunoabsorption (specific xenoantibody removal) [13]. Al-
though this approach has been utilized in ABO hlood tyre-
incompatible human-to-human transplants with some success 
[14], its application to xenotransplantation has been limited owing 
to the rapidity with which the preformed xenoantibodies are 
produced, resulting in the restoration of xenoantibody levels 
leading to hyperacute rejection. To date, little success has been 
achieved in the prevention of xenoantibody synthesis using cyto-
toxic drugs, and alternative approaches must· therefore be taken. 
Preformed xenoantibodies playa vital role in mediating hyper-
acute rejection, but they are not the effector molecules responsi-
ble for the observed damage in discordant xenografts. Antibody 
binding to the xenograft results in activation of complement, most 
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of which is manufactured in the recipient'S liver [15]. These 
proteins exist in an inactive form but are activated when antibody 
binds to the target cells, resulting in damage to the cell. The 
importance of complement in the pathophysiology of antibody-
mediated rejection is shown in studies in which complement is 
depleted. Cobra venom depletes the C3 and C5 components, 
resulting in paralysis of the complement system. Adachi and 
coworkers were able to obtain prolongation of discordant xeno-
graft survival with the addition of cobra venom factor along with 
cyclosporine and an antiplatelet agent [4]. Other evidence of the 
importance of CS in the process of xenograft hyperacute rejection 
is the ability of a sesquiterpene compound with anticomplement 
activity to prolong xenograft survival. K76 is though to block the 
CS step of complement activation, and it accelerates the degra-
dation of CSb [16]. Administration of 200 mglkg to rats undergo-
ing heterotopic guinea pig heart transplantation (discordant com-
bination) resulted in marked prolongation of survival: from 8 
minutes to more than 8 hours [17]. 
Cells express naturally occurring proteins (regulators of com-
plement activation) on their surface that help modulate the effects 
of various complement-activated components. The molecules are 
thought to provide an intrinsic mechanism to limit the amplifica-
tion of complement activation. Homologous restriction factor 
(CD59) and decay accelerating factor (OAF: C055) are two 
proteins that have been described as mediators of complement 
activation. C059 is thought to act by inhibiting the insertion of C9 
into MACs, thereby aborting the terminal attack sequence of 
complement activation [18]. OAF limits the generation of classic 
and alternative complement pathway convertases [19]. The im-
portance of these modulators have been demonstrated by exper-
iments that have enhanced expression of these proteins by gene 
transfection [20]. The activities of these complement modulators 
are though to be species-specific and help to explain the phenom-
enon of "homologous species restriction" [21]. This phenomenon 
is most easily seen when addition of homologous complement to 
susceptible target cells does not effectively cause lysis, whereas 
addition of heterologous complement leads to effective cell lysis. 
Thus following pig-to-human xenotransplantation activated hu-
man complement is not inactivated by the complement-inhibitory 
proteins found on pig cells. 
Cell damage occurs by activation of other inflammatory path-
ways as well. Reactive oxygen metabolites, ptostaglandins, and 
cytokines can be generated by the degradation products of 
complement activation. Polymorphonuclear leucocytes and mac-
rophages are attracted to the site of inflammation because of the 
presence of the C5a fragment, which results in the release of 
lysosomal enzymes and result:mt cell damage. C3b enhances 
adhesion of these cells to damaged cells and enhances binding of 
platelets, which may lead to degranulation and release of vasoac-
tive substances, such as serotonin and histamine, both of which 
increase vascular permeability. 
Thrombosis of the microvasculature is enhanced by the loss of 
membrane-associated heparan sulfate from the endothelial cell 
[22]. Heparan sulfate proteoglycan is present in the endothelial 
cell layer of normal vessels and helps maintain a local anticoag-
ulant environment by activation of antithrombin III, an inhibitor 
of thrombin generation. The release of tissue factors from injured 
cells promotes thrombosis. 
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Previous Clinical Xenotranspiantation Elf'orts 
The shortage of neonatal hearts for treatment of severe cardiac 
anomalies prompted Bailey et al. at Loma Linda University to 
transplant a baboon heart into a human neonate with a hypoplas-
tic left ventricle in 1983 [23]. Although the immunosuppressive 
regimen included cyclosporine, the heart was eventually rejected 
by antibody-mediated mechanisms 20 days after transplantation. 
No further attempts at xenotransplantation were done for almost 
a decade. Within an 8-month period in 1992-1993, three attempts 
at transplantation of liver xenografts were performed in the 
United States. The liver appeared to be a logical starting point 
because of the known relative resistance of the liver to antibody-
mediated rejection [24] as compared to the heart and kidney. Two 
baboon-to-human liver transplants were performed at the Uni-
versity of Pittsburgh [8, 17] and one pig-to-human liver transplant 
at Cedars-Sinai Medical Center in Los Angeles [25]. 
Pig-to-Human Liver Xenotranspklntation 
The recipient of a pig liver, a 26-year-old woman with accelerated 
liver failure due to autoimmune hepatitis, progressed to grade 3-4 
coma. The patient was treated to remove preformed anti-pig 
antibodies using a combination of plasmapheresis and specific 
antibody removal by passing her blood through a set of pig 
kidneys. The immunosuppression was based on cyclosporine, 
cyclophosphamide, prostaglandin E1, and azathioprine. The liver 
was placed in a heterotopic position. The liver appeared to 
function for 20 hours as demonstrated by an initial decrease in 
serum lactate and presence of bile. However, the ammonia level 
did not fall, and by 20 hours after transplantation several clinical 
parameters worsened; the patient died 26 hours after transplan-
tation from brain death. 
The liver appeared to have undergone extensive infarction from 
hyperacute rejection despite lowering the antibody titer using 
plasmapheresis and pig kidney perfusion. Titers of xenoantibodies 
had risen rapidly to pretransplant levels by the time of her death. 
These findings are consistent with a rapid reaccumulation of 
xenoreactive antibodies after inital immunoabsorption [12]. 
Baboon-to-Human Liver Xenotranspklntation 
The clinical courses of the two baboon-to-human liver transplant 
patients are summarized. The first patient was a 35-year-old man 
who had previously undergone splenectomy following a motor 
vehicle accident. He was found to be human immunodeficiency 
virus (HIV)-positive. The second patient was a 62-year-old man. 
In both patients the principal complications of chronic hepatitis B 
were poorly controlled edema. fatigue. ascites. encephalopathy. 
and gastrointestinal bleeding. Because of the nature of their liver 
disease they were not considered candidates for human liver 
transplantation. but because of the severity of complications 
xenotransplantation was considered an experimental option. 
Both patients experienced uneventful intraoperative courses 
following reperfusion of the transplanted baboon liver, and the 
clinical impression was one of immediate function of both xeno-
grafts. Immunosuppression utilized a combination of tacrolimus, 
steroids. prostaglandin E1, and cyclophosphamide. The first pa-
tients awoke promptly after transplantation and was extubated 
after 17 hours. The liver function tests returned toward normal 
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levels by the second posttransplant week, and the transaminases 
returned to normal within the first week. The second patient never 
regained a level of consciousness that permitted weaning from the 
ventilator. In addition, the quality of the liver function in the 
second patient was suboptimal, with persistent hyperbilirubinemia 
during the entire postoperative course. Nevertheless, in both 
patients there was evidence of an adequately functioning liver 
mass, that is, normalization of the coagulation with normal 
prothrombin time, correction of the hyperammonemia, normal 
arterial ketone body ratio (a manifestation of hepatic energy 
stores), and clearance of serum lactate. 
A number of liver biopsies were performed throughout the 
posttransplant course (73). The earliest postperfusion biopsies (4 
hours after perfusion) revealed mild antibody-mediated insult. 
Immunofluorescence revealed binding of immunoglobulin with 
complement deposition, but no endothelial injury or platelet 
aggregation was seen. Polymorphonuclear cell infiltration and 
natural killer (NK) cells were seen in these early biopsy speci-
mens. In the first patient a biopsy specimen obtained on day 12 
revealed Kupffer cell hypertrophy, mild centrilobular hepatocyte 
swelling, and cholestasis with a mild mononuclear portal and 
perivenular infiltrate. This infiltrate was predominantly T cells 
and was consistent with mild cellular rejection with minimal 
antibody injury. Later biopsy specimens were remarkably free of 
rejection, either antibody or cellular. Mild cholestasis was noted in 
some of these later specimens. In the first patient the final 
antemortum biopsy was taken on the 64th posttransplant day and 
revealed obvious bile infarcts, with mural necrosis of segments of 
the septal bile ducts. It is conceivable that the unrecognized biliary 
stasis syndrome was an atypical manifestation of rejection. In the 
second patient a biopsy specimen obtained on the fourth post-
transplant day revealed indirect evidence of antibody-mediated 
rejection, and a subsequent splenectomy was performed. Al-
though both patients eventually died from infectious causes the 
baboon livers were able to sustain life for 70 and 26 days, 
respectively. 
New Concepts 
Until recently, an organ transplant (allograft or xenograft) was 
considered a defenseless entity vulnerable to rejection by the 
recipient immune system. In 1992 Starzl and colleagues demon-
strated the ubiquitous presence of donor bone marrow-derived 
cells in human transplant recipients bearing functioning allografts 
for as long as 30 years after transplantation and termed this 
phenomenon microchimerism [26, 27]. It is postulated that the 
interaction of two coexisting donor and recipient cell populations 
leads to a mutual down-regulation of both recipient and donor 
immune systems (i.e .• ~!,~cific i'lactiv3tion of the recipient im-
mune system to donor'tissue and vice versa). Although the 
concept of down-regulating the recipient immune response (to 
prevent rejection) is intuitive. the requirement for down-regulat-
ing the donor immune response transferred by the transplanted 
organ may not be as obvious. It has long been recognized that an 
activated donor immune response can lead to clinical syndromes. 
such as is seen after bone marrow transplantation. with the 
development of graft-versus-host disease and profound immune 
suppression leading to infectious complications. Verification of 
these findings by extensive laboratory research in animals has led 
several groups to undertake clinical trials to enhance microchi-
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merism using donor bone marrow and hopefully promote full 
acceptance of transplanted human organ (i.e., tolerance). It is 
generally believed that higher levels of microchimerism are asso-
ciated with a greater likelihood of achieving tolerance. Recently a 
number of novel growth factors that enhance the growth of bone 
marrow cells have been utilized in animal models of transplanta-
tion and were demonstrated to augment the level of microchimer-
ism [28, 29]. Both species-specific and species-nonspecific growth 
factors have been used, and the availability of both classes of 
growth factors is important, especially in the realm of alIa- and 
xenotransplanta~ion. 
How can we apply the concept of microchimerism to xenotrans-
plantation? If stable microchimerism of xenogeneic donor bone 
marrow can be accomplished in a human, subsequent transplan-
tation of a xenograft is more likely to be accepted. In addition, 
there is evidence that a radiosensitive bone marrow-derived 
population in the liver is important to the acceptance of that liver 
after transplantation [30]. Lethal irradiation followed by xenoge-
neic bone marrow reconstitution, leading to the development of a 
chimeric donor liver xenograft, may lead to diminished immuno-
genicity and decreased severity of rejection following transplan-
tation. This point was suggested in rodent studies using irradiated 
mouse donors reconstituted with rat bone marrow in which the 
survival of the chimeric xenograft was significantly enhanced [31]. 
Humans have preformed antibodies to pig tissue, which would 
lead to hyperacute rejection of the transplanted xenograft. A 
unique approach has been taken that entails expressing human 
complement inhibitory proteins on pig cells; this has been 
achieved by generating genetically modified pigs that carry the 
genes for human complement inhibitory proteins, either human 
CD59 or DAF [32, 33]. Organs obtained from these transgenic 
pigs enjoy prolonged survival when transplanted across discordant 
barriers into primates, suggesting that the human complement-
inhibitory proteins inserted genetically into the pig organ can 
overcome hyperacute rejection [34]. This was shown in the 
marked prolongation of xenograft survival in heterotopically 
transplanted transgenic pig hearts into unmodified baboons. 
Future Clinical Trials of Xenotransplantation 
It is impossible to overcome hyperacute organ rejection, with the 
establishment of microchimerism and tolerance, using tile current 
approaches to xenotransplantation. However, based on two seem-
ingly independent strategies (i.e., donor bone marrow augmenta-
tion and transgenic donors), one hopes to approach the goal of 
successful discordant xenotransplantation in stepwise advances by 
first overcoming the hyperacute rejection barrier and then achiev-
ing stable chimerism. Only after these goals are achieved will 
clinical xenotransplant trials be feasible. 
We anticipate that this goal will be achieved in a stepwise 
manner. The first step requires reliable establishment of chimeric 
transgenic pigs using xenogeneic human hematopoietic stem cell 
infusion with the use of specific or nonspecific hematopoietic 
growth factors. Using large-animal experimental models, primate 
bone marrow (human [28] and baboon [35]) has been adminis-
tered to discordant recipients, many of whom subsequently devel-
oped evidence for donor primate microchimerism. Based on 
previous studies, it has been necessary to infuse primate bone 
marrow into fetuses or neonates as their functionally immature 
immune system is more amenable to manipulation than that in 
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their adult counterparts. In addition, the number of donor cells in 
these recipients can be enhanced by utilizing hematopoietic 
growth factors, resulting in expansion of primate bone marrow-
derived cells. 
It has been previously shown that successful engraftment of 
allogeneic bone marrow leads to a proportionate replacement of 
bone marrow-derived cells in the tissue and organs of these 
recipients. This is the concept on which we base the utilization of 
organs from these animals for transplantation into primates, as we 
have shown that a bone marrow-derived, radiosensitive popula-
tion in the liver is a primary target for rejection. The rationale for 
utilizing transgenic pigs as the recipient of primate bone marrow 
infusion is that their subsequent use as the donor (after confir-
mation of primate chimerism) can withstand the early onslaught 
of hyperacute rejection following xenotransplantation. 
The last step in the prevention of discordant xenograft rejection 
will be the utilization of donor bone marrow as an adjunct to 
developing tolerance. Therefore donor pig bone marrow must be 
given to primates prior to organ transplantation, and survival of 
chimeric-transgenic xenografts can be utilized as the endpoint for 
measuring success. If this approach is determined to be feasible 
clinical trials can be considered. 
Conclusions 
Myths describing the use of animal organs to save humans have 
been recorded since antiquity. The hypothesis proposed here 
represents a logical step in xenotransplantation research. It builds 
on the area of allotransplantation, immunology, molecular biol-
ogy, pharmacology, biochemistry, and bioengineering. Although 
artificial organ development remains a realistic goal, it is imprac-
tical for immediate needs and for complex organs such as the 
liver. Thousands of patients will die waiting for a donor organ 
unless practical alternatives are developed. We believe that this 
xenotransplant project will yield important new scientific informa-
tion about the immune system and organ rejection, which will be 
invaluable regardless of whether the donor organ is animal or 
human. 
Resume 
C'est grace a un certain nombre d'essals par tatonnement qu'on 
est arrive a definir les especes animaux utilisables pour la xeno-
transplantation. Les premiers resultats enregistres avec Ie chim-
panze, Ie babouin et d'autres primates ont ete tres encourageants. 
L'utilisation d'autres animaux, les especes plus disparates, ont etc, 
par contre, des echecs en raison des problemes immunologiques. 
Les essals de xenotransplantation cliniques a I'avenir seront 
Iimites selon Ie choix des especes d'ani'l'laux ainsi ql!e par Ie type 
d'organes a grefIer. Si les primates ont l'avantage d'avoir une 
similarite genetique (et par consequence une comptabilite poten-
tielle) et les echecs au plan immunologique sont moindres. Ie 
cochon presente d'autres avantages: on les eleve plus facilement, 
leur sensibilite est restreinte et ils sont moins susceptibles 
d'abriter des maladies transmissibles. Le succes de la xenotrans-
plantation difIere selon l'organe transplante. En raison d'une 
resistance importante au rejet dlt aux anticorps, Ie foie est un 
organe de choix qui a Ie plus de chances de sucres a long terme. 
Utiliser la xenotransplantation comme grefIe temporaire, une 
«grefIe relais», dependant, en attendant de pouvoir faire une 
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gre:lfe permanente, pourrait etre la base du depart pour permettre 
de continuer les essais cliniques en ce qui concerne les xenogre:lfes 
du coeur ou du rein. On ne pourrait pas repondre a la question de 
compatibilite metabolique ou de risques d'infection avec precision 
avant que la xenotransplantation ne s'e:lfectue avec succes de 
fa~n reguliere. Base sur une experience Iimitee, les approches 
conventionnelles propres a I'allotransplantation n'amenent pas 
forcement aux succes dans Ie domaine de la xenotransplantation. 
Eviter Ie rejet hyper-aigu avec destruction immediate de la 
xenogre:lfe, soit en utilisant des animaux transgeniques ayant des 
proteines regulatrices du complement humain, soit en modulant 
Ie cible antigenique sur l'organe donneur, represente Ie premier 
etape vers la reussite de la xenotransplantation. La possibilite 
d'etablir une tolerance en creant un etat de chimerisme de la 
moelle osseuse parait etre la cle pour vaincre les problemes 
immunologiques a long terme et eviter les inconvenients d'une 
immunosuppression non-specifique en ce qui concerne les com-
plications infectieuses. La xenotransplantation n'est pas exempte 
de criticismes similaires a ceux qu'on a entendus concernant la 
transplantation d'homme a homme a la fin des annees 1960 et 
debut 1970. Pourtant, la perseverance dans la transplantation 
humaine a ete couronnee de succes. Ce succes a ete Ie resultat 
d'une meilleure comprehension progressive de la biologie du 
rejet, des ameliorations dans la manipulation des medicaments et 
de I'experience. II est possible que la xenotransplantation ne soit 
pas un succes universel avant de voir venir d'autres progres 
technologiques, mais continuer une exploration prudente semble 
justifiee pour definir les domaines d'exploitation qui meritent 
d'etre poursuivis. 
Resumen 
Los ensayos pioneros de xenotrasplantes practicados en la pasa-
das tres decadas han definido las Iimitaciones de las diferentes 
especies que han sido utilizados. EI exito ha sido atormentadora-
mente cercano con el chimpance, el mandril y otros primates. EI 
uso de otras especies mas disimiles se han frustrado por la barrera 
de los xenoanticuerpos. Los intentos futuros de xenotrasplante 
tendran los impedimentos correspondientes a las especies de los 
animales y a la naturaleza de los 6rganos a ser trasplantados. Por 
una parte, los primates donantes tienen la ventaja de la similitud 
genetica (y por consiguiente compatibilidad potencial) y Menor 
riesgo de perdida inmunol6gica. Por otra parte, los cerdos 
donantes son de mas facil crianza, no despiertan sentimientos 
afectuosos y probablemente son de menor riesgo en canto a 
enfermedades transmisibles. Se reconoce que el exito del xeno-
trasplante varia segUn los diferentes organos. Por su resistencia 
relativa al rechazo mediado por anticuerpos, el 6rgano aparece 
como el de mayor probabilidad de exito a largo plazo. Sin 
embargo, la consideraci6n de utilizar xenotrasplante en forma 
temporal, 0 a la manera de "puente" hasta un trasplante defini-
tivo, puede hacer posible la realizaci6n de ensayos clinicos con 
xenotrasplantes de coraz6n 0 de rift6n. Asuntos tales como la 
compatibilidad metab6lica y los riesgos deinfeccion no podran ser 
determinados con certeza hasta cuando se logre exito con el 
xenotrasplante clinico. Con base en una experiencia limitada, se 
piensa que los aproches convencionales del alotrasplante no seran 
exitosos en el xenotrasplante. EI primer paso hacia el exito con el 
xenotrasplante consiste en evitar la destrucci6n inmediata del 
xenoinjerto por el rechazo hiperagudo. 10 cual es posible usando 
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animales transgenicos portadores de proteinas reguladoras del 
complemento 0 por la modulaci6n del blanco antigenico en el 
organo donante. La capacidad para lograr tolerancia mediante el 
establecimiento de un estado de quimerismo de la medula osea 
sera la clave para superar los insultos inmunol6gicos a largo plazo 
y evitar las necesariamente elevadas dosis de inmunosupresi6n no 
especifica que de otra manera se requieren y que se asocian con 
un alto riesgo de complicaciones infecciosas. EI xenotrasplante se 
enfrenta a criticas que recuerdan aquellas elevadas ante los 
trasplantes de humano a humano por los aftos 1960s y 1970s. Y sin 
embargo, con persistencia, el avance con este tipo de trasplante ha 
probado ser altamente exitoso. Tal exito ha sido el resultado de un 
incremento escalonado del rechazo biol6gico, de progresos en el 
manejo de las drogas y de la experiencia. Es posible que el 
xenotrasplante no lIegue a ser universalmente exitoso hasta 
alcanzar mayores avances tecnol6gicos, pero se justifica su caute-
10sa exploraci6n, con miras a identificar aquellas areas para las 
cuales se requieran mayor estudio. 
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